Engineered immune cells take on Hard-to-Treat blood cancers
Disease control
Recruiting now
This early-phase study tests a personalized therapy where a patient's own immune cells are modified to recognize and attack cancer cells. It is for children and adults with certain blood cancers (like leukemia or lymphoma) that have not responded to standard treatments. The goal …
Phase: PHASE1 • Sponsor: Nelson Hamerschlak • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC